Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice

Infection and Immunity

Volumn 75, Issue 10, 2007, Pages 4792-4798

  Kechichian, Talar B ^a   Shea, John ^a   Del Poeta, Maurizio ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDE;

ALKALINITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DISEASE EXACERBATION; DISEASE SEVERITY; EXTRACELLULAR SPACE; FUNGAL CELL; FUNGAL GENE; FUNGAL VIRULENCE; FUNGUS GROWTH; GCS1 GENE; HOST; IMMUNE DEFICIENCY; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; MACROPHAGE ACTIVATION; MOUSE; MUTANT; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

ANIMALS; BRAIN; COLONY COUNT, MICROBIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GLUCOSYLCERAMIDES; GRANULOMA; IMMUNOCOMPROMISED HOST; KIDNEY; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; SPLEEN; SURVIVAL ANALYSIS; VIRULENCE FACTORS;

EID: 34848905334     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00587-07     Document Type: Article

References (34)

1. Alvarez, M., and A. Casadevall. 2006. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16:2161-2165.
2. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans, p. 381-405. ASM Press, Washington, DC.
3. Chang, W. L., H. C. van der Heyde, and B. S. Klein. 1998. Flow cytometric quantitation of yeast a novel technique for use in animal model work and in vitro immunologic assays. J Immunol. Methods 211:51-63.
4. Chang, Y. C., M. F. Stins, M. J. McCaffery, G. F. Miller, D. R. Pare, T. Dam, M. Paul-Satyaseela, K. S. Kim, and K. J. Kwon-Chung. 2004. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72:4985-4995.
5. Chretien, F., O. Lortholary, I. Kansau, S. Neuville, F. Gray, and F. Dromer. 2002. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J. Infect. Dis. 186:522-530.
6. Del Poeta, M. 2004. Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot. Cell 3:1067-1075.
7. Diamond, R. D., and J. E. Bennett. 1973. Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J. Infect. Dis. 127:694-697.
8. Diamond, R. D., and J. E. Bennett. 1973. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect. Immun. 7:231-236.
9. Feldmesser, M., Y. Kress, P. Novikoff, and A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68:4225-4237.
10. Feldmesser, M., S. Tucker, and A. Casadevall. 2001. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol. 9:273-278.
11. Huffnagle, G. B., M. B. Boyd, N. E. Street, and M. F. Lipscomb. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160:2393-2400.
12. Khan, M. A., R. Jabeen, and O. Mohammad. 2004. Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. Pharm. Res. 21:2207-2212.
13. Khan, M. A., R. Jabeen, T. H. Nasti, and O. Mohammad. 2005. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine- containing liposomes in a murine model. J. Antimicrob. Chemother. 55:223-228.
14. Levitz, S. M. 2001. Cryptococcus neoformans: intracellular or extracellular? Trends Microbiol. 9:417-418.
15. Levitz, S. M., S. H. Nong, K. F. Seetoo, T. S. Harrison, R. A. Speizer, and E. R. Simons. 1999. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect. Immun. 67:885-890.
16. Luberto, C., B. Martinez-Marino, D. Taraskiewicz, B. Bolanos, P. Chitano, D. L. Toffaletti, G. M. Cox, J. R. Perfect, Y. A. Hannun, E. Balish, and M. Del Poeta. 2003. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J. Clin. Investig. 112:1080-1094.
17. Lui, G., N. Lee, M. Ip, K. W. Choi, Y. K. Tso, E. Lam, S. Chau, R. Lai, and C. S. Cockram. 2006. Cryptococcosis in apparently immunocompetent patients. QJM 99:143-151.
18. Ma, H., J. E. Croudace, D. A. Lammas, and R. C. May. 2006. Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16:2156-2160.
19. Mansour, M. K., and S. M. Levitz. 2002. Interactions of fungi with phagocytes. Curr. Opin. Microbiol. 5:359-365.
20. Mazzolla, R., R. Barluzzi, A. Brozzetti, J. R. Boelaert, T. Luna, S. Saleppico, F. Bistoni, and E. Blasi. 1997. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob. Agents Chemother. 41:802-807.
21. Mitchell, A. P. 2006. Cryptococcal virulence: beyond the usual suspects. J. Clin. Investig. 116:1481-1483.
22. Perfect, J. R. 2006. Cryptococcus neoformans: a sugar-coated killer, p. 281-303. In J. Heitman, S. G. Filler, J. E. Edwards, Jr., and A. P. Mitchell (ed.), Molecular principles of fungal pathogenesis, vol. 1. ASM Press, Washington, DC.
23. Rittershaus, P. C., T. B. Kechichian, J. Allegood, A. H. J. Merrill, M. Hennig, C. Luberto, and M. Del Poeta. 2006. Glucosylceramide is an essential regulator of pathogenicity of Cryptococcus neoformans. J. Clin. Investig. 116: 1651-1659.
24. Rodrigues, M. L., L. R. Travassos, K. R. Miranda, A. J. Franzen, S. Rozental, W. de Souza, C. S. Alviano, and E. Barreto-Bergter. 2000. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect. Immun. 68:7049-7060.
25. Rozenbaum, R., and A. J. Goncalves. 1994. Clinical epidemiological study of 171 cases of cryptococcosis. Clin. Infect. Dis. 18:369-380.
26. Schofield, D. A., C. Westwater, and E. Balish. 2004. Beta-defensin expression in immunocompetent and immunodeficient germ-free and Candida albicans-monoassociated mice. J. Infect. Dis. 190:1327-1334.
27. Shao, X., A. Mednick, M. Alvarez, N. van Rooijen, A. Casadevall, and D. L. Goldman. 2005. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175:3244-3251.
28. Shea, J., T. B. Kechichian, C. Luberto, and M. Del Poeta. 2006. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C (Isc1) confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect. Immun. 74:5977-5988.
29. Thepen, T., N. Van Rooijen, and G. Kraal. 1989. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J. Exp. Med. 170:499-509.
30. Tucker, S. C., and A. Casadevall. 2002. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99:3165-3170.
31. Van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174:83-93.
32. Wang, B., C. Biron, J. She, K. Higgins, M. J. Sunshine, E. Lacy, N. Lonberg, and C. Terhorst. 1994. A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene. Proc. Natl. Acad. Sci. USA 91:9402-9406.
33. Wang, B., C. Levelt, M. Salio, D. Zheng, J. Sancho, C. P. Liu, J. She, M. Huang, K. Higgins, M. J. Sunshine, et al. 1995. Over-expression of CD3 epsilon transgenes blocks T lymphocyte development. Int. Immunol. 7:435-448.
34. Wang, B., S. J. Simpson, G. A. Hollander, and C. Terhorst. 1997. Development and function of T lymphocytes and natural killer cells after bone marrow transplantation of severely immunodeficient mice. Immunol. Rev. 157:53-60.